Popular weight-loss drugs linked to sudden vision loss, research suggests

Published: Wednesday, August 13, 2025 at 5:19 pm

Weight-Loss Drugs Linked to Potential Vision Concerns, New Research Suggests

Recent studies published in JAMA have raised concerns about the potential impact of popular weight-loss medications on eye health. The research focused on semaglutide and tirzepatide, active ingredients in drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, and their effects on Americans with type 2 diabetes over a two-year period.

One study indicated a modest increase in the risk of developing non-arteritic anterior ischaemic optic neuropathy (NAION), a rare eye condition that can lead to sudden vision loss due to reduced blood flow. Out of over 159,000 participants, 35 developed NAION, compared to 19 in a comparison group. The same study also noted an increased risk of other optic nerve disorders.

While a second study didn't find a statistically significant difference in NAION cases, it did observe a small increase in diabetic retinopathy, a condition that can damage the retina. Despite this, researchers concluded that fewer patients experienced sight-threatening complications from diabetic retinopathy while on these medications.

Experts emphasize the need for regular eye screenings and monitoring for patients with type 2 diabetes who are taking these medications. One medical weight loss doctor suggests that more research is needed to confirm the association between these drugs and vision loss, citing some conflicting results in the studies. She also noted that eye complications are often related to the degree of diabetes control.

The drugs are known to reduce the severity of type 2 diabetes, potentially reducing the incidence of eye diseases. They have also been shown to reduce the risk of cardiovascular disease and improve circulation, which can benefit eye health. The medical weight loss doctor recommends that diabetics starting these medications have an eye exam and schedule follow-up exams.

Novo Nordisk, the manufacturer of Ozempic and Wegovy, stated that patient safety is a priority and that they take all reports of adverse events seriously. They also stated that their analysis of clinical trials does not suggest a causal relationship between GLP-1 receptor agonist use and NAION events.

BNN's Perspective:

The findings warrant further investigation, but it's crucial to avoid alarmism. While the studies suggest a potential link between these medications and vision issues, the risks appear to be modest. Patients should discuss any concerns with their healthcare providers and adhere to recommended screening protocols. The benefits of these drugs in managing diabetes and potentially reducing cardiovascular risks should also be considered.

Keywords: weight loss drugs, vision loss, eye health, semaglutide, tirzepatide, Ozempic, Wegovy, Mounjaro, Zepbound, type 2 diabetes, NAION, diabetic retinopathy, GLP-1, optic nerve disorders, eye disease, Novo Nordisk

Full Story